The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Therapeutic Potential of Boron-Containing Compounds
Abstract
Relative to carbon, hydrogen, nitrogen and oxygen, very little is currently known about boron in therapeutics. In addition, there are very few boron-containing natural products identified to date to serve as leads for medicinal chemists. Perceived risks of using boron and lack of synthetic methods to handle boron-containing compounds have caused the medicinal chemistry community to shy away from using the atom. However, physical, chemical and biological properties of boron offer medicinal chemists a rare opportunity to explore and pioneer new areas of drug discovery. Boron therapeutics are emerging that show different modes of inhibition against a variety of biological targets. With one boron-containing therapeutic agent on the market and several more in various stages of clinical trials, the occurrence of this class of compound is likely to grow over the next decade and boron could become widely accepted as a useful element in future drug discovery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation of a cDNA cLone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis Genome
Choo, Q.-L., Kuo, G., Weiner, A. J., Overby, L. R., Bradley, D. W., & Houghton, M. (1989) · Science · doi:10.1126/science.2523562 · Cited by 6,875
The crisis in antibiotic resistance
Neu, H. C. (1992) · Science · doi:10.1126/science.257.5073.1064 · Cited by 2,834
A functional classification scheme for beta-lactamases and its correlation with molecular structure
Bush, K., Jacoby, G. A., & Medeiros, A. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.6.1211 · Cited by 2,475
Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use
Bender, A. T., & Beavo, J. A. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.5 · Cited by 1,781
Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms
Beavo, J. A. (1995) · Physiological Reviews · doi:10.1152/physrev.1995.75.4.725 · Cited by 1,767
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Boron Neutron Capture Therapy of Cancer: Current Status and Future Prospects
Barth, R. F., Coderre, J. A., Vicente, M. G. H., & Blue, T. E. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0035 · Cited by 1,046
Boronic Acids: Preparation and Applications in Organic Synthesis and Medicine
(2005) · Wiley eBooks · doi:10.1002/3527606548 · Cited by 984
Multimodular Penicillin-Binding Proteins: An Enigmatic Family of Orthologs and Paralogs
Goffin, C., & Ghuysen, J.-M. (1998) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.62.4.1079-1093.1998 · Cited by 636
An Antifungal Agent Inhibits an Aminoacyl-tRNA Synthetase by Trapping tRNA in the Editing Site
Rock, F. L., Mao, W., Yaremchuk, A., Tukalo, M., Crépin, T., Zhou, H., Zhang, Y.-K., Hernandez, V., Akama, T., Baker, S. J., et al. (2007) · Science · doi:10.1126/science.1142189 · Cited by 631
Self-citationBoronic acid compounds as potential pharmaceutical agents
Yang, W., Gao, X., & Wang, B. (2003) · Medicinal Research Reviews · doi:10.1002/med.10043 · Cited by 502
Farci, P. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00051-x · Cited by 467
Phosphodiesterase inhibitors: new opportunities for the treatment of asthma.
Torphy, T. J., & Undem, B. J. (1991) · Thorax · doi:10.1136/thx.46.7.512 · Cited by 380
Deacon, C. F., Hughes, T. E., & Holst, J. J. (1998) · Diabetes · doi:10.2337/diabetes.47.5.764 · Cited by 321
Baker, S. J., Zhang, Y.-K., Akama, T., Lau, A., Zhou, H., Hernandez, V., Mao, W., Alley, M. R. K., Sanders, V., & Plattner, J. J. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0603724 · Cited by 314
Self-citationNarra, K., Mullins, S. R., Lee, H.-O., Strzemkowski-Brun, B., Magalong, K., Christiansen, V. J., McKee, P. A., Egleston, B., Cohen, S. J., Weiner, L. M., et al. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.11.4874 · Cited by 275
Holst, J. J. (1997) · Annual Review of Physiology · doi:10.1146/annurev.physiol.59.1.257 · Cited by 267
A Mechanism of Drug Action Revealed by Structural Studies of Enoyl Reductase
Baldock, C., Rafferty, J. B., Sedelnikova, S. E., Baker, P. J., Stuitje, A. R., Slabas, A. R., Hawkes, T. R., & Rice, D. W. (1996) · Science · doi:10.1126/science.274.5295.2107 · Cited by 239
Akama, T., Baker, S. J., Zhang, Y.-K., Hernandez, V., Zhou, H., Sanders, V., Freund, Y., Kimura, R., Maples, K. R., & Plattner, J. J. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.03.007 · Cited by 218
Self-citationBeta-lactamase-mediated resistance and opportunities for its control
Livermore, D. M. (1998) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/41.suppl_4.25 · Cited by 193
Flentke, G. R., Munoz, E., Huber, B. T., Plaut, A. G., Kettner, C. A., & Bachovchin, W. W. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.4.1556 · Cited by 168
Pauly, R. P., Rosche, F., Wermann, M., McIntosh, C. H. S., Pederson, R. A., & Demuth, H. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.38.23222 · Cited by 154
Molecular Diversity of Cyclic AMP Signalling
Antoni, F. A. (2000) · Frontiers in Neuroendocrinology · doi:10.1006/frne.1999.0193 · Cited by 152
Daily Boron Intake from the American Diet
Rainey, C. J., Nyquist, L., CHRISTENSEN, R. E., Strong, P. L., Culver, B. D., & Coughlin, J. R. (1999) · Journal of the American Dietetic Association · doi:10.1016/s0002-8223(99)00085-1 · Cited by 142
HUMAN METABOLISM OF THE PROTEASOME INHIBITOR BORTEZOMIB: IDENTIFICATION OF CIRCULATING METABOLITES
Pekol, T. M., Daniels, J. S., LaButti, J. N., Parsons, I., Nix, D., Baronas, E., Hsieh, F., Gan, L.-S. L., & Miwa, G. T. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.002956 · Cited by 135
Preparation and antibacterial activities of new 1,2,3-diazaborine derivatives and analogs
Grassberger, M. A., Turnowsky, F., & Hildebrandt, J. (1984) · Journal of Medicinal Chemistry · doi:10.1021/jm00374a003 · Cited by 127
Coutts, S. J., Kelly, T. A., Snow, R. J., et al. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm950732f · Cited by 125
Structure, Function, and Inhibition along the Reaction Coordinate of CTX-M β-Lactamases
Chen, Y., Shoichet, B. K., & Bonnet, R. (2005) · Journal of the American Chemical Society · doi:10.1021/ja042850a · Cited by 120
Bachovchin, W. W., Plaut, A. G., Flentke, G. R., Lynch, M., & Kettner, C. A. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)39656-5 · Cited by 110
Heins, J., Welker, P., Schönlein, C., Born, I., Hartrodt, B., Neubert, K., Tsuru, D., & Barth, A. (1988) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/0167-4838(88)90067-2 · Cited by 106
Therapeutic benefit of PDE4 inhibitors in inflammatory diseases.
Dastidar, S. G., Rajagopal, D., & Ray, A. (2007) · PubMed · Cited by 105
Gupta, R., Walunj, S. S., Tokala, R. K., Parsa, K. V. L., Singh, S. K., & Pal, M. (2009) · Current Drug Targets · doi:10.2174/138945009787122860 · Cited by 105
Baker, S. J., Akama, T., Zhang, Y.-K., Sauro, V., Pandit, C., Singh, R., Kully, M. L., Khan, J., Plattner, J. J., Benkovic, S. J., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.08.130 · Cited by 94
Self-citationA diazaborine derivative inhibits lipopolysaccharide biosynthesis
Högenauer, G., & Woisetschläger, M. (1981) · Nature · doi:10.1038/293662a0 · Cited by 86
Baldock, C., de Boer, G. J., Rafferty, J. B., Stuitje, A. R., & Rice, D. W. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00684-9 · Cited by 83
Tissue Uptake of BSH in Patients with Glioblastoma in the EORTC 11961 Phase I BNCT Trial
Hidéghety, K., Sauerwein, W. A. G., Wittig, A., Goetz, C., Paquis, P., Grochulla, F., Haselsberger, K., Wolbers, J. G., Moss, R. L., Huiskamp, R., et al. (2003) · Journal of Neuro-Oncology · doi:10.1007/bf02699941 · Cited by 78
β-Lactamase-inhibitor combinations in the 21st century: current agents and new developments
Miller, L. A. (2001) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(01)00079-0 · Cited by 75
Connolly, B. A., Sanford, D. G., Chiluwal, A. K., Healey, S. E., Peters, D. E., DiMare, M. T., Wu, W., Liu, Y., Maw, H. H., Zhou, Y., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800390n · Cited by 72
Boron Therapeutics on the Horizon
Groziak, M. P. (2001) · American Journal of Therapeutics · doi:10.1097/00045391-200109000-00005 · Cited by 69
Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update)
Gallwitz, B. (2007) · Drugs of today · doi:10.1358/dot.2007.43.11.1157620 · Cited by 68
Levy, C., Baldock, C., Wallace, A. J., Sedelnikova, S. E., Viner, R. C., Clough, J. M., Stuitje, A. R., Slabas, A. R., Rice, D. W., & Rafferty, J. B. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.4643 · Cited by 62
Syntheses and evaluation of benzodiazaborine compounds against M. tuberculosis H37Rv in vitro
Davis, M. C., Franzblau, S. G., & Martin, A. R. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00126-7 · Cited by 57
Fleming, Y., Frame, M. C., & Houslay, M. D. (2004) · Journal of Cell Science · doi:10.1242/jcs.01096 · Cited by 47
X-ray Crystallography of Surfaces and Interfaces
Robinson, I. (1998) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767398008125 · Cited by 44
Novel β-lactam antibiotics and inhibitor combinations
Bassetti, M., Righi, E., & Viscoli, C. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.3.285 · Cited by 41
Potent inhibitors of HCV-NS3 protease derived from boronic acids
Venkatraman, S., Wu, W., Prongay, A., GIRIJAVALLABHAN, V. M., & Njoroge, F. G. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.10.124 · Cited by 36
Garcia‐Soria, G., González-Gálvez, G., Argoud, G., Gerstman, M., Littlejohn, T. W., Schwartz, S. L., O'Farrell, A. M., Li, X., Cherrington, J. M., Bennett, C., et al. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00868.x · Cited by 29
The mechanism of action of diazaborines
Baldock, C., Rafferty, J. B., de Boer, G. J., Stuitje, A. R., & Rice, D. W. (1998) · Data Archiving and Networked Services (DANS) · Cited by 16
Cited by
Boron-containing inhibitors of synthetases
Baker, S. J., Tomsho, J. W., & Benkovic, S. J. (2011) · Chemical Society Reviews · doi:10.1039/c0cs00131g · Cited by 256
Self-citation
Metadata
- Authors
- Baker, S. J., Ding, C. Z., Akama, T., Zhang, Y.-K., Hernandez, V., & Xia, Y.
- Venue
- Future Medicinal Chemistry
- Publisher
- Informa UK Limited
- Published
- 2009-10
- Volume
- 1
- Issue
- 7
- Pages
- 1275-1288
- ISSN
- 1756-8919 (ISSN-L)
- 1756-8927
- OpenAlex
- W2152933949
- Cited by
- 373
- References
- 48
- FWCI
- 6.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
